SEOM clinical guidelines for myeloid growth factors.
Neutropenia induced by chemotherapy (CT) is an infection risk factor associated to greater morbidity/mortality and dose-limiting toxicity that on many occasions requires a reduction of the dose of cytostatics or a delay in the administration of treatment. This may have a negative effect on the patient's quality of life and even diminish the efficacy of the treatment, especially when the intention is to cure or prolong survival. Management of treatment or prophylaxis of grade 3-4 neutropenia and febrile neutropenia with myeloid growth factors (CSF) varies very much in clinical practice, both in the time of starting treatment and the types of patients it is given to. The need to generalise and facilitate practice based on clinical evidence has led the Spanish Society of Medical Oncology (SEOM) to prepare clinical practice guidelines on the use of myeloid growth factors.
Medical Oncology Unit, Dr. Peset University Hospital, Valencia, Spain. munyoz_joslan@gva.es
José
J
Muñoz Langa
Pere
P
Gascón
Javier
J
de Castro
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D018890:Chemoprevention / Q000379:methods; D003115:Colony-Stimulating Factors / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism / Q000627:therapeutic use*; D008495:Medical Oncology / Q000331:legislation & jurisprudence / Q000458:organization & administration; D022423:Myeloid Cells / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D010166:Palliative Care / Q000379:methods; D012955:Societies, Medical / Q000331:legislation & jurisprudence / Q000458:organization & administration; D013030:Spain
D003115:Colony-Stimulating Factors; D036341:Intercellular Signaling Peptides and Proteins